Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis

Background: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated surgically, whereas hepatomegaly is palliated by radiotherapy (RT). Case Report: A 56-year-old man with advan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology research and treatment 2008-06, Vol.31 (6), p.325-327
Hauptverfasser: Riesterer, Oliver, Gmür, Jürg, Lütolf, Urs
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 327
container_issue 6
container_start_page 325
container_title Oncology research and treatment
container_volume 31
creator Riesterer, Oliver
Gmür, Jürg
Lütolf, Urs
description Background: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated surgically, whereas hepatomegaly is palliated by radiotherapy (RT). Case Report: A 56-year-old man with advanced and drug-refractory myelofibrosis suffered from extensive hepatomegaly with severe upper abdominal pain, satiety, weight loss, and fatigue 1.5 years after splenectomy. The patient was treated periodically with fractionated RT to the liver in order to obtain symptom control and to prevent severe symptom recurrence. Results: After 2 Gy fractionated RT to a treatment field encompassing nearly the whole liver, symptoms improved and liver size decreased without severe side effects. This treatment regimen was successfully conducted 3 times in trimonthly intervals. Because symptoms recurred periodically, we then continued RT on a preemptive basis in monthly intervals and with single-dose irradiation. The patient responded well to 1 Gy preemptive single-dose RT to the liver, but not to 0.5 Gy single-dose partial liver irradiation. Conclusion: RT is effective in palliation of hepatomegaly in advanced myelofibrosis. Even preemptive RT can benefit selected patients with advanced disease and periodical recurrence of symptoms.
doi_str_mv 10.1159/000127399
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000127399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18547974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-bdc601c447b46623227e30d0b33c3029b0c7c4a1104661b6df0778925a20c7a3</originalsourceid><addsrcrecordid>eNpFkM1LAzEUxIMottQevIvk6mE1H7ub5liKWqFiqb0v2eRtG90vsrGy_72xLe3pDcxv5sEgdEvJI6WJfCKEUCa4lBdoyJhMo4Sl7PKkBRmgcdd97bEkmQh5jQZ0ksRCiniI_ApaUB4MVrXBSwdQtd7uAC9VWVq1lytlbOO34FTb46bAn31gmiqYGs-hVUHDRpU9tjVWIegt1B7_Wr_FU7NTtQ7t7z2UTWFz13S2u0FXhSo7GB_vCK1fntezebT4eH2bTReR5lz6KDc6JVTHscjjNGWcMQGcGJJzrjlhMida6FhRSoJN89QURIiJZIliwVF8hB4OtTp87RwUWetspVyfUZL9b5edtgvs_YFtf_IKzJk8LhWAuwPwrdwG3Bk45P8AV-FzBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis</title><source>Karger Journals</source><source>MEDLINE</source><creator>Riesterer, Oliver ; Gmür, Jürg ; Lütolf, Urs</creator><creatorcontrib>Riesterer, Oliver ; Gmür, Jürg ; Lütolf, Urs</creatorcontrib><description>Background: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated surgically, whereas hepatomegaly is palliated by radiotherapy (RT). Case Report: A 56-year-old man with advanced and drug-refractory myelofibrosis suffered from extensive hepatomegaly with severe upper abdominal pain, satiety, weight loss, and fatigue 1.5 years after splenectomy. The patient was treated periodically with fractionated RT to the liver in order to obtain symptom control and to prevent severe symptom recurrence. Results: After 2 Gy fractionated RT to a treatment field encompassing nearly the whole liver, symptoms improved and liver size decreased without severe side effects. This treatment regimen was successfully conducted 3 times in trimonthly intervals. Because symptoms recurred periodically, we then continued RT on a preemptive basis in monthly intervals and with single-dose irradiation. The patient responded well to 1 Gy preemptive single-dose RT to the liver, but not to 0.5 Gy single-dose partial liver irradiation. Conclusion: RT is effective in palliation of hepatomegaly in advanced myelofibrosis. Even preemptive RT can benefit selected patients with advanced disease and periodical recurrence of symptoms.</description><identifier>ISSN: 2296-5270</identifier><identifier>ISSN: 0378-584X</identifier><identifier>EISSN: 2296-5262</identifier><identifier>EISSN: 1423-0240</identifier><identifier>DOI: 10.1159/000127399</identifier><identifier>PMID: 18547974</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Clinical Case · Kasuistik ; Dose Fractionation ; Hepatomegaly - radiotherapy ; Humans ; Male ; Middle Aged ; Palliative Care - methods ; Primary Myelofibrosis - radiotherapy ; Radiotherapy Dosage ; Secondary Prevention</subject><ispartof>Oncology research and treatment, 2008-06, Vol.31 (6), p.325-327</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>(c) 2008 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-bdc601c447b46623227e30d0b33c3029b0c7c4a1104661b6df0778925a20c7a3</citedby><cites>FETCH-LOGICAL-c339t-bdc601c447b46623227e30d0b33c3029b0c7c4a1104661b6df0778925a20c7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18547974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riesterer, Oliver</creatorcontrib><creatorcontrib>Gmür, Jürg</creatorcontrib><creatorcontrib>Lütolf, Urs</creatorcontrib><title>Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Background: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated surgically, whereas hepatomegaly is palliated by radiotherapy (RT). Case Report: A 56-year-old man with advanced and drug-refractory myelofibrosis suffered from extensive hepatomegaly with severe upper abdominal pain, satiety, weight loss, and fatigue 1.5 years after splenectomy. The patient was treated periodically with fractionated RT to the liver in order to obtain symptom control and to prevent severe symptom recurrence. Results: After 2 Gy fractionated RT to a treatment field encompassing nearly the whole liver, symptoms improved and liver size decreased without severe side effects. This treatment regimen was successfully conducted 3 times in trimonthly intervals. Because symptoms recurred periodically, we then continued RT on a preemptive basis in monthly intervals and with single-dose irradiation. The patient responded well to 1 Gy preemptive single-dose RT to the liver, but not to 0.5 Gy single-dose partial liver irradiation. Conclusion: RT is effective in palliation of hepatomegaly in advanced myelofibrosis. Even preemptive RT can benefit selected patients with advanced disease and periodical recurrence of symptoms.</description><subject>Clinical Case · Kasuistik</subject><subject>Dose Fractionation</subject><subject>Hepatomegaly - radiotherapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Palliative Care - methods</subject><subject>Primary Myelofibrosis - radiotherapy</subject><subject>Radiotherapy Dosage</subject><subject>Secondary Prevention</subject><issn>2296-5270</issn><issn>0378-584X</issn><issn>2296-5262</issn><issn>1423-0240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LAzEUxIMottQevIvk6mE1H7ub5liKWqFiqb0v2eRtG90vsrGy_72xLe3pDcxv5sEgdEvJI6WJfCKEUCa4lBdoyJhMo4Sl7PKkBRmgcdd97bEkmQh5jQZ0ksRCiniI_ApaUB4MVrXBSwdQtd7uAC9VWVq1lytlbOO34FTb46bAn31gmiqYGs-hVUHDRpU9tjVWIegt1B7_Wr_FU7NTtQ7t7z2UTWFz13S2u0FXhSo7GB_vCK1fntezebT4eH2bTReR5lz6KDc6JVTHscjjNGWcMQGcGJJzrjlhMida6FhRSoJN89QURIiJZIliwVF8hB4OtTp87RwUWetspVyfUZL9b5edtgvs_YFtf_IKzJk8LhWAuwPwrdwG3Bk45P8AV-FzBg</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Riesterer, Oliver</creator><creator>Gmür, Jürg</creator><creator>Lütolf, Urs</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200806</creationdate><title>Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis</title><author>Riesterer, Oliver ; Gmür, Jürg ; Lütolf, Urs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-bdc601c447b46623227e30d0b33c3029b0c7c4a1104661b6df0778925a20c7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Clinical Case · Kasuistik</topic><topic>Dose Fractionation</topic><topic>Hepatomegaly - radiotherapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Palliative Care - methods</topic><topic>Primary Myelofibrosis - radiotherapy</topic><topic>Radiotherapy Dosage</topic><topic>Secondary Prevention</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riesterer, Oliver</creatorcontrib><creatorcontrib>Gmür, Jürg</creatorcontrib><creatorcontrib>Lütolf, Urs</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riesterer, Oliver</au><au>Gmür, Jürg</au><au>Lütolf, Urs</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2008-06</date><risdate>2008</risdate><volume>31</volume><issue>6</issue><spage>325</spage><epage>327</epage><pages>325-327</pages><issn>2296-5270</issn><issn>0378-584X</issn><eissn>2296-5262</eissn><eissn>1423-0240</eissn><abstract>Background: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated surgically, whereas hepatomegaly is palliated by radiotherapy (RT). Case Report: A 56-year-old man with advanced and drug-refractory myelofibrosis suffered from extensive hepatomegaly with severe upper abdominal pain, satiety, weight loss, and fatigue 1.5 years after splenectomy. The patient was treated periodically with fractionated RT to the liver in order to obtain symptom control and to prevent severe symptom recurrence. Results: After 2 Gy fractionated RT to a treatment field encompassing nearly the whole liver, symptoms improved and liver size decreased without severe side effects. This treatment regimen was successfully conducted 3 times in trimonthly intervals. Because symptoms recurred periodically, we then continued RT on a preemptive basis in monthly intervals and with single-dose irradiation. The patient responded well to 1 Gy preemptive single-dose RT to the liver, but not to 0.5 Gy single-dose partial liver irradiation. Conclusion: RT is effective in palliation of hepatomegaly in advanced myelofibrosis. Even preemptive RT can benefit selected patients with advanced disease and periodical recurrence of symptoms.</abstract><cop>Basel, Switzerland</cop><pmid>18547974</pmid><doi>10.1159/000127399</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-5270
ispartof Oncology research and treatment, 2008-06, Vol.31 (6), p.325-327
issn 2296-5270
0378-584X
2296-5262
1423-0240
language eng
recordid cdi_crossref_primary_10_1159_000127399
source Karger Journals; MEDLINE
subjects Clinical Case · Kasuistik
Dose Fractionation
Hepatomegaly - radiotherapy
Humans
Male
Middle Aged
Palliative Care - methods
Primary Myelofibrosis - radiotherapy
Radiotherapy Dosage
Secondary Prevention
title Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A06%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20and%20Preemptive%20Palliative%20Radiotherapy%20of%20Symptomatic%20Hepatomegaly%20in%20a%20Patient%20with%20Advanced%20Myelofibrosis&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Riesterer,%20Oliver&rft.date=2008-06&rft.volume=31&rft.issue=6&rft.spage=325&rft.epage=327&rft.pages=325-327&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000127399&rft_dat=%3Cpubmed_cross%3E18547974%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18547974&rfr_iscdi=true